AZ505

AZ505 is a potent and selective SMYD2 inhibitor with an IC50 of 0.12 μM.

Product Specifications

CAS Number

[1035227-43-0]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Histone Methyltransferase

Type

Reference compound

Related Pathways

Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/az505.html

Purity

99.99

Solubility

DMSO : ≥ 135 mg/mL

Smiles

O=C(N(C1CCCCC1)CCNCCC2=C(OCC(N3)=O)C3=C(O)C=C2)CCNCCC4=CC=C(Cl)C(Cl)=C4

Molecular Formula

C29H38Cl2N4O4

Molecular Weight

577.54

Precautions

H302, H315, H319, H335

References & Citations

[1]Komatsu S, et al. Overexpression of SMYD2 contributes to malignant outcome in gastric cancer. Br J Cancer. 2015 Jan 20;112 (2) :357-64.|[2]Ferguson AD, et al. Structural basis of substrate methylation and inhibition of SMYD2. Structure. 2011 Sep 7;19 (9) :1262-73.|[3]Li LX, et al. Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease. J Clin Invest. 2017 Jun 30;127 (7) :2751-2764.

Shipping Conditions

Blue Ice

Storage Conditions

-20°C, 3 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

SMYD2

Citation 01

Am J Physiol Renal Physiol. 2022 Aug 1;323 (2) :F227-F242.|Biochem Pharmacol. 2026 Jan;243 (Pt 2) :117562.|Biomedicines. 2024 Oct 8;12 (10) :2279.|Cell Death Dis. 2018 Feb 27;9 (3) :326.|Cell Death Dis. 2021 May 2;12 (5) :439.|Cell Death Dis. 2022 Jan 12;13 (1) :52.|Cell Death Discov. 2022 Jun 6;8 (1) :274.|Cell. 2023 Apr 27;186 (9) :1968-1984.e20.|Cells. 2022 Apr 8;11 (8) :1262.|Clin Exp Pharmacol Physiol. 2025 Jul;52 (7) :e70035.|FASEB J. 2021 Jul;35 (7) :e21715.|J Bone Metab. 2021 Nov;28 (4) :297-305.|J Clin Invest. 2017 Jun 30;127 (7) :2751-2764.|Mol Carcinog. 2023 Aug;62 (8) :1119-1135.|Oncogene. 2021 Apr;40 (15) :2711-2724.|Research Square Preprint. 2021 Oct.|Sci Adv. 2020 Oct 30;6 (44) :eabb3154.|Sci Adv. 2023 Jun 16;9 (24) :eade6624.|Theranostics. 2019 Oct 22;9 (26) :8377-8391. |Development. 2020 Sep 28;147 (18) :dev190678.|Exp Cell Res. 2021 Jul 15;404 (2) :112649.|Mol Carcinog. 2023 Jul;62 (7) :940-950.